Terms: = Prostate cancer AND FLI1, SIC-1, 2313, ENSG00000151702, Q01543, EWSR2 AND Treatment
6 results:
1. High intratumoral plasma cells content in primary prostate cancer defines a subset of tumors with potential susceptibility to immune-based treatments.
Weiner AB; Yu CY; Kini M; Liu Y; Davicioni E; Mitrofanova A; Lotan TL; Schaeffer EM
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):105-112. PubMed ID: 35568781
[TBL] [Abstract] [Full Text] [Related]
2. Transcription factor Fli-1 as a new target for antitumor drug development.
Li L; Yu J; Cheng S; Peng Z; Luo H
Int J Biol Macromol; 2022 Jun; 209(Pt A):1155-1168. PubMed ID: 35447268
[TBL] [Abstract] [Full Text] [Related]
3. Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial.
Chung V; Mansfield AS; Braiteh F; Richards D; Durivage H; Ungerleider RS; Johnson F; Kovach JS
Clin Cancer Res; 2017 Jul; 23(13):3277-3284. PubMed ID: 28039265
[No Abstract] [Full Text] [Related]
4. Transcriptional regulatory networks in human lung adenocarcinoma.
Meng X; Lu P; Bai H; Xiao P; Fan Q
Mol Med Rep; 2012 Nov; 6(5):961-6. PubMed ID: 22895549
[TBL] [Abstract] [Full Text] [Related]
5. YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion.
Rahim S; Beauchamp EM; Kong Y; Brown ML; Toretsky JA; Üren A
PLoS One; 2011 Apr; 6(4):e19343. PubMed ID: 21559405
[TBL] [Abstract] [Full Text] [Related]
6. Adenovirus 5 early region 1A does not induce expression of the ewing sarcoma fusion product EWS-fli1 in breast and ovarian cancer cell lines.
Meric F; Liao Y; Lee WP; Pollock RE; Hung MC
Clin Cancer Res; 2000 Oct; 6(10):3832-6. PubMed ID: 11051226
[TBL] [Abstract] [Full Text] [Related]
